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A B S T R A C T
Background
Traumatic corneal abrasions are relatively common and there is a lack of consensus about analgesia in their management. It is therefore
important to document the clinical efficacy and safety profile of topical ophthalmic non-steroidal anti-inflammatory drugs (NSAIDs)
in the management of traumatic corneal abrasions.
Objectives
To identify and evaluate all randomised controlled trials (RCTs) comparing the use of topical NSAIDs with placebo or any alternative
analgesic interventions in adults with traumatic corneal abrasions (including corneal abrasions arising from foreign body removal), to
reduce pain, and its effects on healing time.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials
Register) (2017, Issue 2), MEDLINE Ovid (1946 to 30 March 2017), Embase Ovid (1947 to 30 March 2017), LILACS (Latin
American and Caribbean Health Sciences Literature Database) (1982 to 30 March 2017), OpenGrey (System for Information on
Grey Literature in Europe) (www.opengrey.eu/); searched 30 March 2017, ZETOC (1993 to 30 March 2017), the ISRCTN registry (
www.isrctn.com/editAdvancedSearch); searched 30 March 2017, ClinicalTrials.gov (www.clinicaltrials.gov); searched 30 March 2017
and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en); searched 30 March 2017. We
did not use any date or language restrictions in the electronic searches for trials.We checked the reference lists of identified trials to
search for further potentially relevant studies.
1Topical non-steroidal anti-inflammatory drugs for analgesia in traumatic corneal abrasions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Selection criteria
RCTs comparing topical NSAIDs to placebo or any alternative analgesic interventions in adults with traumatic corneal abrasions.
Data collection and analysis
Two review authors independently performed data extraction and assessed risks of bias in the included studies. We rated the certainty
of the evidence using GRADE.
Main results
We included nine studies that met the inclusion criteria, reporting data on 637 participants.The studies took place in the UK, USA,
Israel, Italy, France and Portugal. These studies compared five types of topical NSAIDs (0.1% indomethacin, 0.03% flurbiprofen, 0.5%
ketorolac, 1% indomethacin, 0.1% diclofenac) to control (consisting of standard care and in four studies used placebo eye drops).
Overall, the studies were at an unclear or high risk of bias (particularly selection and reporting bias). None of the included studies
reported the primary outcome measures of this review, namely participant-reported pain intensity reduction of 30% or more or 50%
or more at 24 hours. Four trials, that included data on 481 participants receiving NSAIDs or control (placebo/standard care), reported
on the use of ‘rescue’ analgesia at 24 hours as a proxy measure of pain control. Topical NSAIDs were associated with a reduction in the
need for oral analgesia compared with control (risk ratio (RR) 0.46, 95% confidence interval (CI) 0.34 to 0.61; low-certainty evidence).
Approximately 4 out of 10 people in the control group used rescue analgesia at 24 hours. No data were available on the use of analgesia
at 48 or 72 hours.
One trial (28 participants) reported on the proportion of abrasions healed after 24 and 48 hours. These outcomes were similar in both
arms of the trial. (at 24 hours RR 1.00 (0.81 to 1.23); at 48 hours RR 1.00 (0.88 to 1.14); low-certainty evidence). In the control group
nine out of 10 abrasions were healed within 24 hours and all were healed by 48 hours. Complications of corneal abrasions were reported
in 6 studies (609 participants) and were infrequently reported (4 complications, 1 in NSAID groups (recurrent corneal erosion) and 3
in control groups (2 recurrent corneal erosions and 1 corneal abscess), very low-certainty evidence). Possible drug-related adverse events
(AEs) were reported in two trials (163 participants), with the number of adverse events low (4 AEs, 3 in NSAID group, including
discomfort/photophobia on instillation, conjunctival hyperaemia and urticaria, and 1 in the control group, corneal abscess) very low-
certainty evidence.
Authors’ conclusions
The findings of the included studies do not provide strong evidence to support the use of topical NSAIDs in traumatic corneal abrasions.
This is important, since NSAIDs are associated with a higher cost compared to oral analgesics. None of the trials addressed our primary
outcome measure of participant-reported pain intensity reduction of 30% or more or 50% or more at 24 hours.
P L A I N L A N G U A G E S U M M A R Y
Topical non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of pain in traumatic corneal abrasions
What is the aim of this review?
The aim of this Cochrane Review was to find out if topical (applied directly to the surface of the eye) non-steroidal anti-inflammatory
drugs (NSAIDs) for traumatic corneal abrasions reduce pain. Cochrane researchers collected and analysed all relevant studies to answer
this question. We found nine studies.
Key messages
It is unclear if using topical NSAIDs is helpful in traumatic corneal abrasions. Topical NSAIDs cost more to use than alternative
treatments such as oral pain-killing tablets.
What was studied in the review?
A corneal abrasion is a scratch on the cornea of the eye. The cornea is the clear window that is in front of the iris, which is the coloured
part of the eye. The cornea is important both for vision and for protecting the eye.When a corneal abrasion occurs, it causes significant
pain and discomfort. A traumatic corneal abrasion is a corneal abrasion caused by an injury, such as the eye being poked or something
like dirt or sand being trapped under the eyelid and scratching the cornea.
NSAIDs are one form of pain management for people with corneal abrasions.They may reduce the pain.
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What are the main results of the review?
The Cochrane researchers found nine relevant studies. Three studies each were from the UK and the USA, one from Italy, one from
Israel and one from France/Portugal. These studies used five types of topical NSAIDs (0.1% indomethacin, 0.03% flurbiprofen, 0.5%
ketorolac, 1% indomethacin, 0.1% diclofenac). The studies compared the topical NSAIDs with antibiotic eye drops, artificial tears,
eye patching and dummy (placebo) eye drops. Three of the studies were funded by the manufacturer while the other six studies did
not report their funding source.
The results of the review show that:
It is unclear if people treated with topical NSAIDs experience a clinically meaningful reduction in pain compared with people being
treated with placebo or standard care (antibiotic eye drops, artificial tears, eye patching) but they may use less oral pain killers.
Where drug-related side effects, and complications of corneal abrasion (e.g. poor healing or infection) were reported (in two trials),
the numbers were low.
How up-to-date is this review?
Cochrane researchers searched for studies that had been published up to March 2017.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Topical NSAIDs compared to control for analgesia in traumatic corneal abrasions
Patient or population: analgesia in traumatic corneal abrasions
Setting: hospital emergency departments
Intervention: topical NSAIDs
Comparison: placebo/ standard care
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with Placebo/
usual care
Risk with Topical
NSAIDs
Part icipant-reported
pain intensity reduct ion
of 30%/ 50% or greater
at 24 hours
See comment See comment N/ A N/ A N/ A None of the included
studies reported the
primary outcome mea-
sures for this review
Use of rescue oral anal-
gesia at 24 hours
400 per 1,000 184 per 1,000
(136 to 244)
RR 0.46
(0.34 to 0.61)
481
(4 RCTs)
⊕⊕©©
LOW1
-
Use of rescue oral anal-
gesia at 48/ 72 hours
See comment See comment N/ A N/ A N/ A None of the included
studies reported rescue
analgesia at 48 hours or
at 72 hours as an out-
come measure
Proport ion of abrasions
healed af ter 24 hours
900 per 1,000 900 per 1,000
(729 to 1,000)
RR 1.00
(0.81 to 1.23)
28
(1 RCT)
⊕⊕©©
LOW1
-
Proport ion of abrasions
healed af ter 48 hours
1,000 per 1,000 1000 per 1,000
(880 to 1,000)
RR 1.00
(0.88 to 1.14)
28
(1 RCT)
⊕⊕©©
LOW1
-
Complicat ions of
corneal abrasion
10 per 1,000 4 per 1,000
(1 to 29)
RR 0.44
(0.07 to 2.96)
609
(6 RCTs)
⊕©©©
VERY LOW1,2
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Drug-related adverse
events
10 per 1,000 30 per 1,000
(3 to 276)
RR 2.95
(0.32 to 27.60)
163
(2 RCTs)
⊕©©©
VERY LOW1,2
-
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High-certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate-certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low-certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low-certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded two levels for lim itat ions in study design and implementat ion
2Downgraded one level for imprecision (wide conf idence intervals that cross the null ef fect)
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B A C K G R O U N D
Description of the condition
A corneal abrasion results from a disruption in the integrity of
the corneal epithelium and generally results from physical exter-
nal forces scraping the corneal surface (Wilson 2004). Traumatic
corneal abrasions are very common ophthalmic injuries and repre-
sent a significant healthcare burden to general emergency depart-
ments (EDs), ophthalmology emergency departments and Gen-
eral Practitioners (Chiapella 1985; Edwards 1987; Fenton 2001;
Shields 1991). In one study, ophthalmic emergencies accounted
for 6.1% of all ED attendances at a district general hospital over
a 12-month period; 65% of these were trauma-related, of which
24% were corneal abrasions (Edwards 1987). Traumatic corneal
abrasions also represent a significant economic burden on society
in general. For example, in the USA, corneal abrasions account
for approximately 15% of all work-related eye diseases that cause
missed time from work (Harris 2008).
A traumatic corneal abrasion is also associated with significant pa-
tient morbidity. Its diagnosis is suggested by a history of recent
ocular trauma (usually unilateral) and subsequent acute pain, tear-
ing, photophobia, foreign body sensation, with or without effects
on visual acuity (blurred vision). Other symptoms include: pain
with extraocular musclemovement, blepharospasm and headache.
Deeper scratches can cause corneal scarring that can impair vision
to the point where corneal transplantation is needed. Recurrent
corneal erosion may follow corneal trauma and can produce dis-
abling ocular symptoms and predispose the cornea to infection
(Watson 2013).
Description of the intervention
Although current treatment recommendations for traumatic
corneal abrasions stress the use of topical antibiotics and topical
(ophthalmic) or oral analgesics (Wilson 2004), there is no uni-
versal consensus regarding corneal abrasion management (Sabri
1998). Routine use of topical anaesthetics is not recommended,
due to recognised corneal complications associated with their use
(Pharmakakis 2002; Yagci 2011). Most corneal abrasions heal
with the use of topical antibiotics (drops or ointment) and anal-
gesics (topical (ophthalmic) or oral). Regarding management of
the pain associated with corneal abrasions, topical ophthalmic
non-steroidal anti-inflammatory drugs (NSAIDs) have demon-
strable efficacy, particularly where potential opioid-induced seda-
tion is intolerable (Weaver 2003). However, there is also no con-
sensus regarding management of the pain caused by traumatic
corneal abrasions. A national survey of 470 members of the Cana-
dian Association of Emergency Physicians revealed wide variation
in pain management preferences for traumatic corneal abrasions;
these included oral analgesics (82.1%), cycloplegics (65.1%) and
topical NSAIDs (52.8%) (Calder 2004).
There have been scattered reports of adverse effects, including
cornealmelting, associatedwith topical NSAIDs, particularly after
cataract surgery, concurrent use of topical steroids and prolonged
administration (Guidera 2001; Lin 2000). A previous systematic
review of the use of the topical NSAIDs for corneal abrasions failed
to perform a meta-analysis of adverse effects due to insufficient
data (Calder 2005).
How the intervention might work
Topical NSAID use results in a clinically significant decrease in
pain (by an average of 1.3 cms on a standard 10-cm pain scale),
a decrease in oral analgesic use and a decrease in requirement for
narcotic analgesia (Weaver 2003). Topical NSAID use has been
shown to be associated with earlier return to work after a traumatic
corneal abrasion (Kaiser 1997).
Why it is important to do this review
The use of topical NSAIDs for the management of pain in trau-
matic corneal abrasions is a clinically valid topic for a Cochrane
Review for many reasons. Firstly, corneal abrasions are relatively
common. Secondly, they are associated with significant morbidity,
healthcare costs and societal economic burden. Thirdly, there is a
lack of consensus regarding analgesia in traumatic corneal abra-
sions. Fourthly, as the use of topical ophthalmic NSAIDs is very
common, it is important to document any incidence of adverse
effects when used in the management of traumatic corneal abra-
sions. Furthermore, a Cochrane Review that is continuously up-
dated as new evidence is published may lead to clinical practice
guidelines whichmay improve the efficiency and quality of patient
care (Edwards 1987; Fenton 2001; Thyagarajan 2006). Moreover,
the last non-Cochrane systematic review on this topic was pub-
lished almost twelve years ago (Calder 2005). This Cochrane Re-
view aims to synthesise the current best evidence, which will be
continuously updated as relevant new trials are published, regard-
ing the role of topical NSAIDs for analgesia in traumatic corneal
abrasions (including corneal abrasions arising from foreign body
removal).
O B J E C T I V E S
To identify and evaluate all randomised controlled trials (RCTs)
comparing the use of topical NSAIDs with placebo or any al-
ternative analgesic interventions in adults with traumatic corneal
abrasions (including corneal abrasions arising from foreign body
removal) to reduce pain, and its effects on healing time.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs in all languages. A RCT was defined as a study
in which participants were allocated to treatment groups on the
basis of a method to generate a random sequence (for example,
using random-number tables).
We did not include studies with cross-over designs because these
are not appropriate designs for the clinical condition of interest in
this review and for this research question.
Types of participants
We included adults aged 18 and over with traumatic corneal abra-
sion(s) (including corneal abrasions arising from foreign body re-
moval).
Types of interventions
The target intervention was topical NSAIDs (dose as defined by
study authors, either overall daily dose or number of drops per
day) in adults with traumatic corneal abrasions (including corneal
abrasions arising from foreign body removal), compared to the
following interventions:
1. Administration of cycloplegics (e.g. cyclopentolate drops,
homatropine drops).
2. Administration of oral analgesics (e.g. NSAIDs, opioids,
paracetamol/acetaminophen).
3. Administration of ocular lubricants (e.g. artificial tears
(hydrogels)).
4. Administration of topical antibiotics (e.g. chloramphenicol,
fusidic acid, trimethoprim/polymyxin).
5. Eye patching.
Types of outcome measures
Primary outcomes
1. Participant-reported pain intensity reduction of 30% or
more at 24 hours (dichotomous data).
2. Participant-reported pain intensity reduction of 50% or
more at 24 hours (dichotomous data).
Secondary outcomes
1. Use of ’rescue’ analgesia (i.e. oral analgesia) at 24 hours, 48
hours and 72 hours.
2. Percentage/proportion healed after 24 and 48 hours
(healing should have been ascertained using fluorescein staining
or slit-lamp examination).
3. Complications of corneal abrasion (e.g. corneal ulceration,
corneal infections, recurrent corneal erosion syndrome) as
defined by the study authors.
4. Whether the use of concurrent topical antibiotics (drops or
ointments) with additional lubricating effects reduced pain.
Adverse effects (severe, minor)
We looked for the following adverse effects:
1. Drug-related adverse events (e.g. corneal melting, corneal
scarring, allergic conjunctivitis or keratitis secondary to ocular
medications).
2. Other adverse events as defined by the study authors.
Search methods for identification of studies
Electronic searches
The Cochrane Eyes and Vision Information Specialist conducted
systematic searches in the following databases for randomised con-
trolled trials and controlled clinical trials. There were no language
or publication year restrictions. The date of the search was 30
March 2017.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 2) (which contains the Cochrane Eyes
and Vision Trials Register) in the Cochrane Library (searched 30
March 2017) (Appendix 1);
• MEDLINE Ovid (1946 to 30 March 2017) (Appendix 2);
• Embase Ovid (1980 to 30 March 2017) (Appendix 3);
• LILACS (Latin American and Caribbean Health Science
Information database (1982 to 30 March 2017) (Appendix 4);
• OpenGrey (System for Information on Grey Literature in
Europe) (www.opengrey.eu/; searched 30 March 2017)
(Appendix 5);
• ZETOC (1993 to 30 March 2017) (Appendix 6);
• ISRCTN registry (www.isrctn.com/editAdvancedSearch;
searched 30 March 2017) (Appendix 7);
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov; searched 30 March
2017) (Appendix 8);
• World Health Organization International Clinical Trials
Registry Platform (www.who.int/ictrp; searched 30 March 2017)
(Appendix 9).
Searching other resources
We made additional efforts to identify potential RCTs relevant to
the topic from the references (and references of references) cited
in primary sources. We did not impose any language restriction.
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Data collection and analysis
Selection of studies
Two review authors (RM and OG) independently assessed the
titles and abstracts of studies identified by relevance and design.
We obtained full-text versions of the articles if they appeared to
meet the inclusion criteria in the initial assessment of studies. A
third review author (AW) evaluated any discrepant judgements.
Data extraction and management
Two review authors (MB and MQ) independently extracted data
using a standardised data collection form that included informa-
tion on the name of the first author, year of publication, study de-
sign, study population and study setting. In addition to informa-
tion pertaining to participant characteristics, study inclusion and
exclusion criteria, details of the interventions compared and study
outcomes, we extracted information on study methodology. This
included the method of randomisation, allocation concealment,
frequency and handling of withdrawals, and adherence to the in-
tention-to-treat principle.We resolved disagreements through dis-
cussion and in consultation with a third review author (AW) as
required.
Assessment of risk of bias in included studies
Two review authors (MB and MQ) independently assessed and
rated the methodological quality of each trial using the Cochrane
tool for assessing risk of bias as in Chapter 8 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We judged the quality of the studies by evaluating them for the
following domains:
1. Random sequence generation.
2. Allocation concealment.
3. Masking of participants and personnel, and outcome
assessment.
4. Incomplete outcome data.
5. Selective outcome reporting.
6. Funding source.
7. Other potential sources of bias.
We evaluated each study and assessed it separately for these do-
mains. We judged each explicitly as follows:
• Low risk of bias.
• High risk of bias.
• Unclear risk (lack of information or uncertainty over the
potential for bias).
We entered the data on what was reported to have happened in
the study in the ’Risk of bias’ table in Review Manager 5 (Review
Manager 5 2014). We present summary figures of the ’risk of bias
in included studies’ in the review. These provides a context for
discussing the reliability of the results of this review. We resolved
any disagreement by referring to a third review author (AW) to
reach a consensus.
Measures of treatment effect
We calculated summary estimates of treatment effect with 95%
confidence intervals (CIs) for each comparison. Our measure of
treatment effect was the risk ratio (RR) for dichotomous outcomes
and the mean difference (MD) for continuous outcomes. Cur-
rently the review only includes analysis of dichotomous outcomes.
Unit of analysis issues
The unit of randomisation was the eye of individual trial partic-
ipants. We did not anticipate that studies would have more than
one eye affected in each individual; however, if this occurred we
planned to note it in the review. If studies using a paired design
were eligible for inclusion (i.e. studies assigning one eye to treat-
ment and the fellow eye to control), we planned to use the generic
inverse variance method to combine the results of such studies
with those of studies randomising only one eye for each partici-
pant.
Dealing with missing data
No simple solution exists for the problem of missing data. We
planned to handle this problem by contacting the investigators,
whenever possible, to ensure that no data were missing for their
study. We also planned to make explicit the assumptions of what-
ever method we used to cope with missing data.
Assessment of heterogeneity
We evaluated clinical heterogeneity (differences between studies
in key characteristics of the participants, interventions or outcome
measures). In the absence of clinical heterogeneity, we used the I2
statistic to describe the percentage of total variation across studies
that is due to heterogeneity rather than chance (Higgins 2003).
An I2 greater than 50% may represent substantial or consider-
able statistical heterogeneity (Higgins 2011). The importance we
placed on the observed value of I2 depended on (i) magnitude and
direction of effects, and (ii) strength of evidence for heterogeneity
(P value from the Chi2 test and confidence interval for I2).
We also used visual inspection of the graphic representation of
studies with their 95% CIs to assess heterogeneity. We generated
tables and graphs using the analysis module included in RevMan
(Review Manager 5 2014). We represent pooled risk ratios picto-
rially as a ’forest plots’ to permit visual examination of the degree
of heterogeneity between studies.
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Assessment of reporting biases
We assessed reporting bias through careful attention to quality
assessment, particularly methodology. We planned to use funnel
plot analysis to assess publication bias if there were more than
10 studies included in the meta-analysis. We also planned to use
the Egger test (Egger 1997) to assess funnel plot asymmetry. A
thorough search for unpublished studies through grey literature
searches and contact with known experts in the field also helped
to reduce the risk of publication bias.
Data synthesis
The results concentrate on the objectives and comparisons spec-
ified in the protocol for our review. We pooled data using a ran-
dom-effects model, because it was likely that the effects of topical
NSAIDs may vary between studies. The random-effects model
takes into account between-study variability as well as within-
study variability. When there were three or fewer trials, we used a
fixed-effect model. We performed meta-analyses using RevMan 5
software (Review Manager 5 2014).
Subgroup analysis and investigation of heterogeneity
We planned to investigate heterogeneity by performing two sub-
group analyses based on intuitive reasons. Firstly, we planned to
perform subgroup analysis of different types of topical NSAIDs
(for example, subgroup analysis of topical diclofenac and topical
ketorolac). Secondly, we planned to perform subgroup analysis of
traumatic corneal abrasions with different aetiologies, based on
whether the abrasions are iatrogenic (arising from foreign body
removal) or non-iatrogenic in origin.
Sensitivity analysis
Finally, we planned to perform sensitivity analyses to test how sen-
sitive the results were to reasonable changes in the assumptions
that we made and in the methods for combining the data (Lau
1998). We planned to perform sensitivity analysis for randomised
versus quasi-randomised studies and eventually good-quality stud-
ies versus poor-quality studies.
Summary of findings
We used the principles of the GRADE system (Lau 1998) to assess
the quality of the body of evidence associated with the primary
outcome measure of this review (pain relief ), and constructed a
’Summary of findings’ (SoF) table using the GRADE software
(GRADEpro 2014). The GRADE approach appraises the quality
of a body of evidence based on the extent to which one can be
confident that an estimate of effect or association reflects the item
being assessed. The quality of a body of evidence considers within-
study risk of bias (methodological quality), the directness of the
evidence, heterogeneity of the data, precision of effect estimates
and risk of publication bias.
R E S U L T S
Description of studies
Results of the search
The electronic searches yielded 465 references (Figure 1). After
134 duplicate were removed the Cochrane Information Specialist
(CIS) screened the remaining 331 records and removed 267 ref-
erences which were not relevant to the scope of the review. We
screened the remaining 64 references and obtained the full-text
reports of nine references for further assessment. We assessed the
nine full-text versions of the abstracts and all met the a priori
criteria for inclusion in the final analysis. See Characteristics of
included studies for details.We did not identify any ongoing stud-
ies from our searches of the clinical trials registries.
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Figure 1. Study flow diagram.
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Included studies
We included nine studies in this review (Alberti 2001; Brahma
1996; Donnenfeld 1995; Goyal 2001; Jayamanne 1997; Kaiser
1997; Patrone 1999; Solomon 2000; Szucs 2000). The interven-
tions compared in this review were diverse (Table 1).
Excluded studies
We did not exclude any study after obtaining the full text of the
report.
Risk of bias in included studies
We evaluated the overall quality of each study according to the
methodology detailed in Assessment of risk of bias in included
studies. The Characteristics of included studies table presents dif-
ferent ’Risk of bias’ domains. Figure 2 and Figure 3 present a graph
and summary of the risk of bias of included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Random sequence generation
Two of the studies (Brahma 1996; Donnenfeld 1995) were at a
high risk of bias due to an inadequate method of sequence genera-
tion. We rated five of the studies at an unclear risk, since there was
no explicit statement about the method for sequence generation.
Allocation concealment
Eight of the studies had an unclear risk of bias because there was
no explicit statement about allocation concealment.
Blinding
Performance bias
In one study, the nature of the interventions was such that double-
masking was not feasible (Solomon 2000). In two of the included
studies, there was no explicit statement about masking of partici-
pants or study personnel (Brahma 1996; Patrone 1999).
Detection bias
There was a high risk of detection bias in one of the studies (
Donnenfeld 1995). In four of the included studies there was a
low risk of bias (Goyal 2001; Jayamanne 1997;Solomon 2000;
Szucs 2000). The risk of detection bias was unclear in four studies
because no explicit statement about masking of outcome assessors
was reported (Alberti 2001; Brahma 1996; Kaiser 1997; Patrone
1999).
Incomplete outcome data
Three of the included studies had a high risk of attrition bias
(Brahma 1996; Patrone 1999; Solomon 2000).
Selective reporting
We judged all studies to have an unclear risk, since no protocol or
trial registry entry was available and it was therefore not possible
to assess this domain.
Other potential sources of bias
We did not identify any other potential sources of bias.
Given the relatively small number of included trials, we were un-
able to assess publication bias (Higgins 2011).
Effects of interventions
See: Summary of findings for the main comparison Topical
NSAIDs compared to control for analgesia in traumatic corneal
abrasions
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Primary outcome measures
None of the included studies reported the primary outcome mea-
sures of this review (participant-reported pain intensity reduction
of 30% or more at 24 hours and participant-reported pain inten-
sity reduction of 50% or more at 24 hours).
Secondary outcome measures
Use of ’rescue’ analgesia (that is, oral analgesia) at 24 hours,
48 hours and 72 hours
Four studies reported ’rescue’ analgesia at 24 hours as an outcome
measure (Alberti 2001; Brahma 1996; Goyal 2001;Szucs 2000)
(participants reported = 481). Although these studies employed
different comparators (Table 1), we pooled the data, since the
treatment effect was in the same direction and the results were
consistent. Participants taking NSAIDs were less likely to require
rescue analgesia (low-certainty evidence); (risk ratio (RR) 0.46,
95% confidence interval (CI) 0.34 to 0.61; Analysis 1.1; Figure
4).
Figure 4. Forest plot of comparison: 1 Topical NSAIDs versus placebo/standard care, outcome: 1.1 Use of
rescue oral analgesia at 24 hours.
None of the included studies reported ’rescue’ analgesia at 48 hours
or at 72 hours as an outcome measure.
Percentage/proportion healed after 24 and 48 hours (healing
should have been ascertained using fluorescein staining or
slit-lamp examination)
One study reported the proportion of corneal abrasions that were
healed after 24 and 48 hours (Solomon 2000) (participants re-
ported =28).Ninety-three per cent of abrasionswere healedwithin
24 hours and the remainder within 48 hours. There was no differ-
ence in the proportion of abrasions healed between groups (low-
certainty evidence); 24 hours (RR 1.00, 95% CI 0.81 to 1.23); 48
hours (RR 1.00, 95% CI 0.88 to 1.14; Analysis 1.2 and Analysis
1.3).
Complications of corneal abrasion (as defined by the study
authors)
Six of the studies reported complications of corneal abrasion as
an outcome measure (Alberti 2001; Brahma 1996; Goyal 2001;
Jayamanne 1997; Kaiser 1997; Szucs 2000) (participants re-
ported = 609). Four of these studies (Brahma 1996; Goyal 2001;
Jayamanne 1997; Szucs 2000) reported no complications in either
study arm. One study (Alberti 2001) reported a corneal abscess
in the comparator group and one study (Kaiser 1997) reported
that three participants returned with a recurrent corneal erosion
(two in the control group and one in the NSAID group) (very
low-certainty evidence); (RR 0.44, 95% CI 0.07 to 2.96; Analysis
1.4).
Whether the use of concurrent topical antibiotics with
additional lubricating effects reduced pain
None of the studies reported whether use of concurrent topical
antibiotics (drops or ointments) with additional lubricating effects
reduced pain.
Drug-related adverse events
Two studies reported on drug-related adverse events as an outcome
measure (Alberti 2001; Jayamanne 1997) (participants reported
= 163). Jayamanne 1997 reported no drug-related events, while
Alberti 2001 reported four events (three in the NSAID group,
including discomfort/photophobia on instillation, conjunctival
hyperaemia and urticaria and one in the control group, corneal
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abscess) very low-certainty evidence; (RR 2.95 95% CI 0.32 to
27.60; Analysis 1.5).
Other adverse events (as defined by the study authors)
None of the nine included studies reported other adverse events
as an outcome measure.
D I S C U S S I O N
Summary of main results
None of the included studies reported the primary outcome mea-
sures of this review, namely participant-reported pain intensity re-
duction of 30% or more or of 50% or more at 24 hours. A 30%
reduction in pain intensity represents a clinically important dif-
ference in pain severity that corresponds to patients’ perception of
adequate pain control (Lee 2003; Younger 2009).
Four trials that randomised 664 participants (481 reported) to
receive NSAIDs or placebo/standard care reported on the use of
‘rescue’ analgesia at 24 hours as a proxy measure of pain control.
These trials were associated with a reduction in the need for oral
analgesia (RR 0.46, 95% CI 0.34 to 0.61).
One trial, in which 28 participants were randomised, reported on
the proportion of abrasions healed after 24 and 48 hours. These
levels were similar between both arms of the trial.
Two trials (163 participants randomised) reported on drug-related
adverse events, with rates low and similar between the intervention
and control groups.
Overall completeness and applicability of
evidence
The review has revealed a lack of high-quality evidence to support
the use of topical NSAIDs in traumatic corneal abrasion.
Quality of the evidence
Despite seven of the nine included studies being conducted fol-
lowing the publication of the CONSORT statement in 1996, the
trials were generally poorly reported. Allocation concealment was
unclear and in the absence of a protocol or trial registration it was
not possible to assess reporting bias. Several of the trials were as-
sociated with missing outcome data that were sufficient to have a
clinically relevant impact on the effect estimate.
Potential biases in the review process
As far as we are aware, we have minimised potential biases in the
review process. We followed all methods set out in the published
protocol and all potentially eligible studies were included. Assess-
ment or risk of bias was limited by poor reporting and the absence
of published protocols or trial registration.
Agreements and disagreements with other
studies or reviews
A previous systematic review of topical NSAIDs for corneal abra-
sions (Calder 2005) included 11 RCTs, of which three were in-
cluded in a meta-analysis of self-reported pain scores at 24 hours.
NSAIDs were found to reduce self-reported pain (weighted mean
difference (WMD) -1.3 (95% CI -1.03 to 1.56)). The authors of
this review concluded that topical NSAIDs can provide effective
analgesia for people with traumatic corneal abrasions.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Traumatic corneal abrasions are a common presentation in both
general emergency departments and specialist eye units. However,
there remains a lack of high-quality evidence to inform the man-
agement of this condition. Prophylactic antibiotics with or with-
out cycloplegia are typically used, although based on the results of
a previous Cochrane Review (Lim 2016) eye patching is no longer
recommended. Most simple traumatic abrasions heal within one
or two days, but during this period they can be associated with
significant pain, foreign body sensation and photophobia. It has
been suggested that topical NSAIDs may be used to provide ef-
fective analgesia, which could potentially reduce the requirement
for oral analgesia, although there have been some concerns in the
literature regarding possible impairment of corneal wound healing
and drug-induced adverse reactions.
The findings from the trials included in this review do not provide
strong evidence to support the use of topical NSAIDs in traumatic
corneal abrasions. This is important, since topical NSAIDs are
associated with a higher cost compared to oral analgesics. None of
the trials addressed our primary outcome measure of participant-
reported pain intensity reduction of 30% or more or 50% or more
at 24 hours.
Although there was some evidence from four trials that the use of
topical NSAIDs led to a reduced need for ’rescue’ analgesia at 24
hours, this finding should be interpreted with caution, since the
certainty of the evidence was low.
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Implications for research
Investigators planning future trials on the effectiveness of topi-
cal NSAIDs for corneal abrasions should attempt to address the
sources of bias identified in the studies included in this review;
specifically the use of appropriate methods for randomisation and
allocation concealment. Furthermore, strategies should be devel-
oped to improve collection of outcome data and reduce attrition
bias. Although the use of unidimensional visual analogue scales
(VASs) has been shown to be a valid and reproducible method
in studies evaluating pain relief, investigators may be tempted to
overestimate the clinical importance of small differences in VAS
scores. Further work in this context should attempt to determine
the minimum clinically important difference as measured by VAS
pain scores that represents small, moderate, or large treatment ef-
fects.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alberti 2001
Methods Study design: double-masked, randomised controlled trial
Study centre: multicentre (6 sites)
Number randomised: 126
Losses to follow-up: 3
Number analysed: 123
Sample size calculation: not reported
Participants Country: France and Portugal
Age (SD): 38.1 (15.9)
% Male: 82.1%
Inclusion Criteria: outpatients of either sex, aged over 18 years, with traumatic corneal
abrasion or requiring ablation of a superficial corneal foreign body and/or curettage, and
in whom the pain due to the lesion was > 20 mm on a horizontal VAS; 0 mm = no pain,
100 mm = unbearable pain
Exclusion criteria: previous intolerance to the tested products or any NSAID or amino-
glycoside, local or systemic anti-inflammatory treatment within the 5 days before the
initial visit, systemic analgesia within the 24 hours before the initial visit, evolutive oc-
ular pathology, any other concomitant traumatic lesion of the eye, deep corneal lesion,
abrasions caused by contact lenses or chemical agents, plant foreign body still present on
the cornea at the initial visit, complications of a traumatic corneal lesion requiring any
treatment other than the study treatments, and monophthalmia
Interventions Intervention: indomethacin 0.1%/gentamicin sulfate 300,000 IU/100 mL eye drops, 4
times daily for 4 - 5 days
Comparator: gentamicin sulfate 300 mg/100 mL eye drops, 4 times daily for 4 - 5 days
Interventions received by both groups: none
Other study arms not included in this review: none
Length of follow-up: 4 - 5 days
Outcomes Primary outcome(s): pain on a horizontal VAS
Secondary outcome(s): evaluation of associated symptoms (photophobia, tearing, burning,
irritation and foreign body sensation on a 0 - 3 scale (0 = absent; I = mild; 2 = moderate;
3 = severe); conjunctival hyperaemia and ciliary injection at day 0, day 1, and day 4/5
visits using the same 0 - 3 severity scale; surface area of the corneal abrasion at each visit;
use of systemic analgesics
Adverse events reported (Y/N): Y
Intervals at which outcome(s) assessed: baseline (T0), one hour after first treatment instil-
lation (T1), one hour after the second treatment instillation on day 0 (T2) and then on
day 1 and day 4 or 5
Notes Study dates: January to June 1998
Trial registration: not reported
Funding source(s): Laboratoire Chauvin
Declaration of interest: not reported
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Alberti 2001 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomisation list was estab-
lished using the PROC RANUNI proce-
dure (SAS® Institute).” p235
Allocation concealment (selection bias) Unclear risk Comment: there is no explicit statement
about the method used to conceal alloca-
tion
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “This was a randomised, double-
masked, parallel- group study carried out
from January to June ’98 at six centres, in
France and Portugal.” p234
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: there is no explicit statement
about masking of outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: > 80% follow-up. Reasons for
missing data provided and any imbalance
unrelated to the outcome
Selective reporting (reporting bias) Unclear risk Comment: no protocol or trial registry en-
try available and therefore not possible to
assess
Brahma 1996
Methods Study design: randomised controlled trial
Study centre: single centre
Number randomised: 401
Losses to follow-up: 177
Number analysed: 224
Sample size calculation: stated that statistical advice was sought to determine sample size
for a significance level of 5%
Participants Country: UK
Age (SD): 33.7 (SD not reported)
% Male: 80.6%
Inclusion criteria: participants with corneal abrasions and foreign bodies attending an
emergency eye centre
Exclusion criteria: participants < 16 years; pregnant women; those with a history of herpes
simplex keratitis; known hypersensitivity to NSAIDs
19Topical non-steroidal anti-inflammatory drugs for analgesia in traumatic corneal abrasions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Brahma 1996 (Continued)
Interventions Interventions: flurbiprofen 0.03% eye drops 4 times daily for 48 hours; homatropine 2%
eye drops at presentation only and flurbiprofen 0.03% eye drops 4 times daily for 48
hours
Comparators: polyvinyl alcohol 1.4% (Liquifilm Tears) 4 times daily for 48 hours; homa-
tropine 2% eye drops at presentation only
Interventions received by all groups: chloramphenicol 1% eye ointment, 4 times daily for
5 days
Other study arms not included in this review: none
Length of follow-up: 24 hours
Outcomes Primary outcome(s): ocular pain on a 10-cm linear VAS (where 0 = no pain and 10 =
worst pain ever experienced)
Secondary outcome(s): oral analgesia (Y/N); sleep disturbance (normal/disturbed); time
off work due to eye injury
Adverse events reported (Y/N): Y
Intervals at which outcome(s) assessed: every 6 hours for 24 hours
Notes Study dates: August 1993 - December 1993
Trial registration: not reported
Funding source(s): Allergan UK provided study medications
Declaration of interest: “None of the authors has any financial interest in Allergan Ther-
apeutics”
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Patients were consecutively allo-
cated at random to one of four treatment
groups (table1)”. p186
Allocation concealment (selection bias) Unclear risk Comment: there is no explicit statement
about the method used to conceal alloca-
tion
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: there is no explicit statement
about masking of participants and study
personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: there is no explicit statement
about masking of outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: high attrition (> 40%). Missing
data likely to bias results
Selective reporting (reporting bias) Unclear risk Comment: no protocol or trial registry en-
try available and therefore not possible to
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assess
Donnenfeld 1995
Methods Study design: single-masked, randomised controlled trial
Study Centre: multicentre (2 sites)
Number randomised: Not reported
Losses to follow-up: Not reported
Number analysed: 47
Sample size calculation: not reported
Participants Country: USA
Age (SD): 34.9 (11.7)
% Male: Not reported
Inclusion criteria: traumatic corneal abrasion of < 24-hour duration
Exclusion criteria: monocular vision; a history of wound healing problems (e.g. collagen
vascular disease or corticosteroid use); usage of other ocular medications or oral NSAIDs;
dry eyes; blepharitis; systemic infections; and contact lens-related epithelial defects
Interventions Intervention: ketorolac tromethamine 0.5% eye drops, 4 times daily
Comparator: placebo (Tears Plus), 4 times daily
Interventions received by both groups: bandage contact lens, single instillation of cyclopen-
tolate 1% eye drops, polymyxin B sulphate/trimethoprim hemisulfate eye drops 4 times
daily
Other study arms not included in this review: single instillation of polymyxin B sulphate/
trimethoprim hemisulfate, single instillation of cyclopentolate 1% and a standard pres-
sure patch
Length of follow-up: 1 - 3 days (until resolution of corneal epithelial defect)
Outcomes Primary outcome(s): time to resolution of corneal epithelial defect
Secondary outcome(s): level of pain, photophobia, ocular irritation, redness, headache,
tearing; ability to return to normal activities
Adverse events reported (Y/N): Y
Intervals at which outcome(s) assessed: psychometric testing at baseline and follow-up day
1, corneal epithelial defect monitored to resolution
Notes Study dates: June 1993 - April 1994
Trial registration: not reported
Funding source(s): Lions Club International; Allergan Pharmaceuticals
Declaration of interest: not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Patients were assigned randomly
to one of three treatment groups.” p 980
Comment: there are no details on the
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Donnenfeld 1995 (Continued)
method of randomisation. Although par-
ticipantswere “randomly assigned” to 1of 3
groups, from the results table, the randomi-
sation seemed to be highly predictable, i.e.
case numbers in each group were separated
by 3
Allocation concealment (selection bias) Unclear risk Comment: there is no explicit statement
about the method used to conceal alloca-
tion
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “This was done in a single-masked
randomised fashion.The patients in groups
B and C were instructed to administer
a drop of both the polymyxin B sulfate/
trimethoprim sulfate and the contents of
the masked bottle four times daily, 5 min-
utes apart.” p 980
Comment: study described as ’single
masked’ and study personnel were un-
masked
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Forty-seven consecutive patients
with traumatic corneal abrasions were ran-
domised prospectively in a single-masked,
controlled clinical trial ...” p 980
Comment: “Single-masked” was referring
to the participant, therefore, assessors were
not masked to the allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: data on all participants reported
Selective reporting (reporting bias) Unclear risk Comment: no protocol or trial registry en-
try available and therefore not possible to
assess
Goyal 2001
Methods Study design: double-masked, randomised controlled trial
Study Centre: single centre
Number randomised: 88
Losses to follow-up: 3
Number analysed: 85
Sample size calculation: sample size calculated on basis of 80% power and significance
level of 5%
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Participants Country: UK
Age (SD): 39.5 (SD not reported)
% Male: 77%
Inclusion criteria: corneal abrasion within the last 48 hours; foreign body removal within
the last 48 hours; age 16 - 80 yrs; no prior treatment
Exclusion criteria: contact lens wear; signs of infiltration or infection; large erosion
of corneal surface; previous corneal surface disease (e.g. corneal dystrophies)
Interventions Intervention: ketorolac trometamol 0.5% eye drops, 4 times daily
Comparator: placebo (Liquifilm Tears), 4 times daily
Interventions received by both groups: single instillation of cyclopentolate 0.5% eye drops;
cyclopentolate 1% ointment
Other study arms not included in this review: N/A
Length of follow-up: followed up daily until complete healing had occurred
Outcomes Primary outcome(s): improvement in pain, photophobia grittiness, wateriness and blurred
vision (assessed using a VAS where 0 = no symptoms and 5 = worst symptoms)
Secondary outcome(s): corneal epithelial healing; use of oral analgesics
Adverse events reported (Y/N): Y
Intervals at which outcome(s) assessed: psychometric testing at baseline and 24 hours
Notes Study dates: not reported
Trial registration: not reported
Funding source(s): not reported
Declaration of interest: not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: no explicit statement about the
method of randomisation
Allocation concealment (selection bias) Unclear risk Comment: there is no explicit statement
about the method used to conceal alloca-
tion
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Neither the examining doctor nor
the patient was aware as to the nature of the
drops.” p 177
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Neither the examining doctor nor
the patient was aware as to the nature of the
drops.” p 177
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Eighty-eight patients were en-
rolled in the study. Three were excluded as
they either did not fulfil the eligibility cri-
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teria or had failed to attend for follow [up].
” p 177
Comment: > 95% of participants com-
pleted the study
Selective reporting (reporting bias) Unclear risk Comment: no protocol or trial registry en-
try available and therefore not possible to
assess
Jayamanne 1997
Methods Study design: double-masked, randomised controlled trial
Study centre: single centre
Number randomised: 40
Losses to follow-up: 0
Number analysed: 40
Sample size calculation: not reported
Participants Country: UK
Age (SD): not reported
% Male: not reported
Inclusion criteria: participants aged > 18 years presenting within 24 hours of a unilateral
corneal abrasion and no other injury
Exclusion criteria: previous corneal pathology, including dystrophies and recurrent ero-
sion syndrome, diabetes, those under 18 years of age or with known hypersensitivity to
either NSAIDs or chloramphenicol
Interventions Intervention: diclofenac 0.1% eye drop 4 times daily in the affected eye
Comparator: normal saline eye drop 4 times daily in the affected eye
Interventions received by both groups: chloramphenicol eye ointment
Other study arms not included in this review: none
Length of follow-up: until complete healing had occurred (all healed within 96 hours)
Outcomes Primary outcome(s): pain measured with a VAS (a horizontal line measuring 10 cm in
length showing a continuum from“nopain” to “worst pain ever”); categorical scale (none,
mild discomfort not requiring painkillers, moderate pain requiring painkillers or severe
disabling pain); and sub-categorisation into foreign body sensation, light sensitivity and
headache-like deep pain within the eye and rating for the sub-categories as none, mild,
moderate or severe
Secondary outcome(s): none
Adverse events reported (Y/N): Y
Intervals at which outcome(s) assessed: baseline (day 0), day 1, day 2
Notes Study dates: not reported
Trial registration: not reported
Funding source(s): not reported
Declaration of interest: not reported
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Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly assigned
to one of two treatment groups.” p 79
Comment: there is no explicit statement
about the method of randomisation
Allocation concealment (selection bias) Unclear risk Comment: there is no explicit statement
about the method used to conceal alloca-
tion
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The drops were dispensed in un-
marked containers.” p 79
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Doctors involved in the patient as-
sessments were masked as to the study drug
codes.” p 80
Quote: “...no unmasking of patients oc-
curred during the trial.” p 80
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “All patients completed the study
as planned...”. p 80
Selective reporting (reporting bias) Unclear risk Comment: no protocol or trial registry en-
try available and therefore not possible to
assess
Kaiser 1997
Methods Study design: double-masked, randomised controlled trial.
Study centre: single centre
Number randomised: not reported (100 enrolled)
Losses to follow-up: not reported (12 failed to complete due to ineligibility or loss to
follow-up)
Number analysed: 88
Sample size calculation: not reported
Participants Country: USA
Age (SD): 38.5 (9.0)
% Male: 83%
Inclusion criteria: aged >18 years, with traumatic corneal abrasionor removal of superficial
corneal foreign body of < 36 hours in duration; simple epithelial defect without stromal
oedema, loss, or infiltrate; no prior treatment before being entered into the study; no
other signs of ocular trauma; and no previous history of eye trauma or disease in the
affected eye
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Kaiser 1997 (Continued)
Exclusion criteria: contact lens wear or had abrasions greater than 10 mm2 in area
Interventions Intervention: ketorolac tromethamine 0.5% ophthalmic solution 4 times daily
Comparator: control vehicle drops 4 times daily
Interventions received by both groups: cycloplegic drops (cyclopentolate 1% /phenyle-
phrine 2.5%/tropicamide 0.25%) and erythromycin or polymyxin B (Polysporin) oph-
thalmic ointment
Other study arms not included in this review: none
Length of follow-up: not reported
Outcomes Primary outcome(s): subjective symptoms: photophobia, tearing, foreign body sensation,
and ”blurry vision“; level of pain assessed on a scale of 0 - 10, with 0 representing no
pain and 10 representing severe pain
Secondary outcome(s): ability to return to normal activities
Adverse events reported (Y/N): Y
Intervals at which outcome(s) assessed: baseline (day 0), day 1, day 2
Notes Study dates: not reported
Trial registration: not reported
Funding source(s): not reported
Declaration of interest: not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”Patients were randomly assigned
in the eye emergency ward by the treating
physician, who obtained an ocular medica-
tion bottle marked “A” or “B.” p 1354
Comment: there is no explicit statement
about the method of randomisation
Allocation concealment (selection bias) Low risk Quote: “The contents of bottle ”A“ or ”B“
were known only by the two authors, who
did not enrol patients in the study.” p 1354
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Both the physician and the patient
were unaware ofwhich bottle contained the
ketorolac tromethamine 0.5% ophthalmic
solution.” p 1354
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: there is no explicit statement
about masking of outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: low attrition and missing data
balanced across arms
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Selective reporting (reporting bias) Unclear risk Comment: no protocol or trial registry en-
try available and therefore not possible to
assess
Patrone 1999
Methods Study design: randomised controlled trial
Study centre: single centre
Number randomised: 409
Losses to follow-up: 62
Number analysed: 347
Sample size calculation:not reported
Participants Country: Italy
Age (SD): 43.4 (15.7)
% Male: 66.5%
Inclusion criteria: corneal abrasion < 16 mm2; no limbus and/or ocular structure involve-
ment; occurred less than 12 hours before the clinical examination; no chronic ocular
pathology or systemic pathologies or neurological/corneal pathologies able to influence
corneal sensitivity; absence of corneal sensitivity impairments to the contralateral un-
damaged eye
Exclusion criteria: participants with abrasions caused by thermal, radiant or caustic agents;
contact lens-wearing participants; and one-eyed or functionally one-eyed participants
Interventions Intervention: indomethacin 0.1% eye drops; netilmicin 0.3% every 4 hours
Comparator: 0.3% netilmicin only every 4 hours
Interventions received by both groups: bandage contact lens for 24 hours
Other study arms not included in this review: N/A
Length of follow-up: not recorded (monitored daily until healing of corneal abrasion)
Outcomes Primary outcome(s): Subjective pain was evaluated using a VPS
Secondary outcome(s): none
Adverse events reported (Y/N): N
Intervals at which outcome(s) assessed: 30 mins after the first medication (T0); during the
first check-up (after 12 hours; T1), and during the second check-up (after 24 hours; T2)
Notes Study dates: January 1994 - February 1997
Trial registration: not reported
Funding source(s): not reported
Declaration of interest: “The authors have no proprietary or financial interest in the
development or marketing of this or any competing drug.”
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Patrone 1999 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “The protocol randomised the pa-
tients into two homogeneous groups.” p
351
Comment: there is no explicit statement
about the method used for randomisation
Allocation concealment (selection bias) Unclear risk Comment: there is no explicit description
about allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: there is no explicit statement
about masking of study participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: there is no explicit statement
about masking of outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Of the 409patientswho joined the
study, 62 were excluded because they failed
to respect the instructions of the protocol.
” p 352
Comment: there were no data on the out-
comes of the 62 excluded participants or
reasons for dropout
Selective reporting (reporting bias) Unclear risk Comment: no protocol or trial registry en-
try available and therefore not possible to
assess
Solomon 2000
Methods Study design: randomised controlled trial
Study centre: single centre
Number randomised: 28
Losses to follow-up: 0
Number analysed: 28
Sample size calculation: not reported
Participants Country: Israel
Age (SD): 32 (SD not reported)
% Male: not reported
Inclusion criteria: corneal epithelial abrasion (3 mm or less) following minor corneal
trauma
Exclusion criteria: not reported
Interventions Intervention: indomethacin 1%, 4 times daily
Comparator: semi-pressure patch
Interventions received by both groups: single instillation of topical cyclopentolate 1% and
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chloramphenicol 0.3%, 3 times daily
Other study arms not included in this review: none
Length of follow-up: 24 hours
Outcomes Primary outcome(s): pain, graded on a scale of 0 - 10; other symptoms including tearing,
itching, burning, discharge, foreign body sensation, and photophobia graded on a scale
from 0 - 3
Secondary outcome(s): objective signs including swelling or hyperaemia of the eyelid and
conjunctival hyperaemia evaluated on a scale of 0 - 3; healing of corneal abrasion
Adverse events reported (Y/N): N
Intervals at which outcome(s) assessed: 6 - 9 hours after start of treatment follow-up 18 -
24 hours after the first visit
Notes Study dates: not reported
Trial registration: not reported
Funding source(s): not reported
Declaration of interest: not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly assigned
into 1 of 2 treatment protocols.” p 317
Comment: there is no explicit statement
about the method of randomisation
Allocation concealment (selection bias) Unclear risk Comment: there is no explicit statement
about the allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: the nature of the comparator
interventions were such that masking was
not feasible
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The first eye examination was al-
ways performed by 1 of the authors (M.H.
), whereas the follow-up examination was
done by another author (J.F.-P.), who was
unaware of the treatment used.” p 317
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “After 6 to 9 hours, we recorded
symptoms in 10 of the 14 patients in group
1 and 11 of the 14 patients in group 2; the
other patients were not available.” p 317
Comment: > 20% attrition for assessment
at 9 hours, which may have biased results
Selective reporting (reporting bias) Unclear risk Comment: no protocol or trial registry en-
try and therefore not possible to assess
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Szucs 2000
Methods Study design: double-masked, randomised controlled trial
Study centre: single centre
Number randomised: 49
Losses to follow-up: 0
Number analysed: 49
Sample size calculation: stated that sample size calculation was performed to determine
the number of participants for a specified outcome
Participants Country: USA
Age (SD): 39.5 (SD not reported)
% Male: 73%
Inclusion criteria: aged 18 years or older with a traumatic corneal abrasion
Exclusion criteria: history of recent eye surgery, glaucoma, ocular infection, other signs
of ocular trauma; adverse reactions to diclofenac or NSAIDs including aspirin; any
narcotic use within 6 hours of ED treatment; unavailable for telephone follow-up at 2
hours; minimal pain defined as a score of 3 or less on the NPIS; pregnancy, women of
childbearing age in whom pregnancy could not be excluded by history of last menstrual
period, and lactating women
Interventions Intervention: single instillation of diclofenac 0.1% eye drops in the ED and then every 6
hours for 24 - 36 hours
Comparator: control vehicle (Natural Tears)
Interventions received by both groups: single instillation of cyclopentolate 0.5% eye
drops, at the discretion of the treating physician; gentamicin 0.3% eye drops, every 2
hours for 24 hours
Other study arms not included in this review: N/A
Length of follow-up: 24 hours
Outcomes Primary outcome(s): improvement of pain 2 hours after treatment
Secondary outcome(s): need for rescue oral analgesia
Adverse events reported (Y/N): Y
Intervals at which outcome(s) assessed: 2 hours after start of treatment
Notes Study dates: not reported
Trial registration: not reported
Funding source(s): not reported
Declaration of interest: not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Eligible patients who had corneal
abrasions detected by fluorescein uptake
during slit lamp examination who signed
consent were then randomly assigned by
our institution’s Pharmacy Investigational
and Clinical Services using a Ciba-Geigy
Scientific Random Number Table to re-
30Topical non-steroidal anti-inflammatory drugs for analgesia in traumatic corneal abrasions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Szucs 2000 (Continued)
ceive either diclofenac or control vehicle
drops.” p 132
Allocation concealment (selection bias) Unclear risk Comment: there is no explicit statement
about the allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Blinding was maintained with the
use of identically labelled and masked bot-
tles. The contents of the bottles were not
visible through the masking.” p 132 - 33
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The patient, physician, and
nurse remained blinded to the medication
throughout the entire study.” p 133
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “We did not have complete follow-
up for 1 patient who was reexamined by
an ophthalmologist. This patient was ulti-
mately excluded from the study. Pain scores
at 2 hours were obtained for all patients en-
rolled in the study.” p133
Selective reporting (reporting bias) Unclear risk Comment: no protocol or trial registry en-
try and therefore not possible to assess
ED: emergency department
NPIS: numerical pain intensity score
IU: international units
NSAID: non-steroidal anti-inflammatory drug
RCT: randomised controlled trial
VAS: visual analogue scale
VPS: verbal pain scale
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D A T A A N D A N A L Y S E S
Comparison 1. Topical NSAIDs versus Control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Use of rescue oral analgesia at 24
hours
4 481 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.34, 0.61]
2 Proportion of abrasions healed
after 24 hours
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Proportion of abrasions healed
after 48 hours
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Complications of corneal
abrasion
6 609 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.07, 2.96]
5 Drug-related adverse events 2 163 Risk Ratio (M-H, Fixed, 95% CI) 2.95 [0.32, 27.60]
Analysis 1.1. Comparison 1 Topical NSAIDs versus Control, Outcome 1 Use of rescue oral analgesia at 24
hours.
Review: Topical non-steroidal anti-inflammatory drugs for analgesia in traumatic corneal abrasions
Comparison: 1 Topical NSAIDs versus Control
Outcome: 1 Use of rescue oral analgesia at 24 hours
Study or subgroup Topical NSAID Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Alberti 2001 4/62 4/61 4.7 % 0.98 [ 0.26, 3.76 ]
Brahma 1996 29/109 66/115 69.7 % 0.46 [ 0.33, 0.66 ]
Goyal 2001 7/43 21/42 15.4 % 0.33 [ 0.15, 0.68 ]
Szucs 2000 5/25 10/24 10.1 % 0.48 [ 0.19, 1.20 ]
Total (95% CI) 239 242 100.0 % 0.46 [ 0.34, 0.61 ]
Total events: 45 (Topical NSAID), 101 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.08, df = 3 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 5.27 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours NSAID Favours Control
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Analysis 1.2. Comparison 1 Topical NSAIDs versus Control, Outcome 2 Proportion of abrasions healed
after 24 hours.
Review: Topical non-steroidal anti-inflammatory drugs for analgesia in traumatic corneal abrasions
Comparison: 1 Topical NSAIDs versus Control
Outcome: 2 Proportion of abrasions healed after 24 hours
Study or subgroup Favours NSAID Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Solomon 2000 13/14 13/14 1.00 [ 0.81, 1.23 ]
0.5 0.7 1 1.5 2
Favours NSAID Favours Control
Analysis 1.3. Comparison 1 Topical NSAIDs versus Control, Outcome 3 Proportion of abrasions healed
after 48 hours.
Review: Topical non-steroidal anti-inflammatory drugs for analgesia in traumatic corneal abrasions
Comparison: 1 Topical NSAIDs versus Control
Outcome: 3 Proportion of abrasions healed after 48 hours
Study or subgroup Favours NSAID Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Solomon 2000 14/14 14/14 1.00 [ 0.88, 1.14 ]
0.01 0.1 1 10 100
Favours NSAID Favours Control
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Analysis 1.4. Comparison 1 Topical NSAIDs versus Control, Outcome 4 Complications of corneal abrasion.
Review: Topical non-steroidal anti-inflammatory drugs for analgesia in traumatic corneal abrasions
Comparison: 1 Topical NSAIDs versus Control
Outcome: 4 Complications of corneal abrasion
Study or subgroup Topical NSAID Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Alberti 2001 0/62 1/61 35.6 % 0.33 [ 0.01, 7.90 ]
Brahma 1996 0/109 0/115 Not estimable
Goyal 2001 0/43 0/42 Not estimable
Jayamanne 1997 0/20 0/20 Not estimable
Kaiser 1997 1/43 2/45 64.4 % 0.52 [ 0.05, 5.56 ]
Szucs 2000 0/25 0/24 Not estimable
Total (95% CI) 302 307 100.0 % 0.44 [ 0.07, 2.96 ]
Total events: 1 (Topical NSAID), 3 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours NSAID Favours Control
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Analysis 1.5. Comparison 1 Topical NSAIDs versus Control, Outcome 5 Drug-related adverse events.
Review: Topical non-steroidal anti-inflammatory drugs for analgesia in traumatic corneal abrasions
Comparison: 1 Topical NSAIDs versus Control
Outcome: 5 Drug-related adverse events
Study or subgroup Topical NSAID Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alberti 2001 3/62 1/61 100.0 % 2.95 [ 0.32, 27.60 ]
Jayamanne 1997 0/20 0/20 Not estimable
Total (95% CI) 82 81 100.0 % 2.95 [ 0.32, 27.60 ]
Total events: 3 (Topical NSAID), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours NSAID Favours Control
A D D I T I O N A L T A B L E S
Table 1. Comparator interventions of included studies
Study Intervention 1 Intervention 2 Comparator 1 Comparator 2
Alberti 2001 Topical
NSAID (indomethacin 0.
1%) + topical antibiotic
None Topical antibiotic None
Brahma 1996 Topical NSAID (flur-
biprofen 0.03%) + topical
antibiotic
Topical NSAID + cyclo-
plegic + topical antibiotic
Placebo + topical antibi-
otic
Cycloplegic +
topical antibiotic
Donnenfeld 1995 Topical NSAID (ketoro-
lac 0.5%) +
cycloplegic + topical an-
tibiotic + bandage CL
None Cycloplegic + topical an-
tibiotic + bandage CL
Cycloplegic + topical an-
tibiotic + pressure patch
Goyal 2001 Topical NSAID (ketoro-
lac 0.5%) + cycloplegic +
topical antibiotic
None Placebo + cycloplegic +
topical antibiotic
None
Jayamanne 1997 Topi-
cal NSAID (diclofenac 0.
None
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Table 1. Comparator interventions of included studies (Continued)
1%) + topical antibiotic
Kaiser 1997 Topical NSAID (ketoro-
lac 0,1%) + cycloplegic +
topical antibiotic
None Placebo + cycloplegic +
topical antibiotic
None
Patrone 1999 Topical NSAID
(indomethacin 0.1%) +
topical antibiotic + ban-
dage CL
None Topical antibiotic + ban-
dage CL
None
Solomon 2000 Topical NSAID in-
domethacin 1%) + cyclo-
plegic + topical antibiotic
None Cycloplegic + topical an-
tibiotic + pressure patch
None
Szucs 2000 Topical NSAID
(diclofenac 0.1%) +
cycloplegic + topical an-
tibiotic
None Placebo+ cycloplegic +
topical antibiotic
None
CL: contact lens
NSAID: non-steroidal anti-inflammatory drug
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Cornea
#2 MeSH descriptor Corneal Diseases
#3 MeSH descriptor Eye Injuries
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Wounds and Injuries
#6 injur* or abrasion* or erosion* or trauma* or wound* or foreign bod*
#7 (#5 OR #6)
#8 eye* or cornea*
#9 (#7 AND #8)
#10 (#4 OR #9)
#11 MeSH descriptor Anti-Inflammatory Agents, Non-Steroidal
#12 nsaid*
#13 nonsteroidal anti-inflammator*
#14 non-steroidal anti-inflammator*
#15 MeSH descriptor Diclofenac
#16 diclofenac*
#17 fenoprofen*
#18 flurbiprofen*
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#19 MeSH descriptor Indomethacin
#20 indometacin*
#21 MeSH descriptor Ketoprofen
#22 ketoprofen*
#23 ketorolac*
#24 piroxicam*
#25 bromfenac*
#26 nepafenac*
#27 oxyphenbutazone*
#28 suprofen*
#29 (#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25
OR #26 OR #27 OR #28)
#30 MeSH descriptor Analgesia
#31 analgesi*
#32 MeSH descriptor Pain
#33 pain*
#34 (#30 OR #31 OR #32 OR #33)
#35 (#10 AND #29 AND #34)
Appendix 2. MEDLINE OVID search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp cornea/
14. exp corneal diseases/
15. exp eye injuries/
16. or/13-15
17. exp “wounds and injuries”/
18. (injur$ or abrasion$ or erosion$ or trauma$ or wound$ or foreign bod$).tw.
19. or/17-18
20. (eye$ or cornea$).tw.
21. 19 and 20
22. 16 or 21
23. exp anti inflammatory agents non steroidal/
24. nsaid$.tw.
25. nonsteroidal anti-inflammator$.tw.
26. non-steroidal anti-inflammator$.tw.
27. exp diclofenac/
28. diclofenac$.tw.
29. fenoprofen$.tw.
30. flurbiprofen$.tw.
31. exp indometacin/
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32. indometacin$.tw.
33. exp ketoprofen/
34. ketoprofen$.tw.
35. ketorolac$.tw.
36. piroxicam$.tw.
37. bromfenac$.tw.
38. nepafenac$.tw.
39. oxyphenbutazone$.tw.
40. suprofen$.tw.
41. or/23-40
42. exp analgesia/
43. analgesi$.tw.
44. Pain/
45. pain$.tw.
46. or/42-45
47. 22 and 41 and 46
48. 12 and 47
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
Appendix 3. Embase OVID search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
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32. 11 or 24 or 31
33. exp cornea/
34. exp cornea disease/
35. exp cornea epithelium/
36. exp eye injury/
37. or/33-36
38. exp injury/
39. (injur$ or abrasion$ or erosion$ or trauma$ or wound$ or foreign bod$).tw.
40. or/38-39
41. (eye$ or cornea$).tw.
42. 40 and 41
43. 37 or 42
44. exp nonsteroidal antiinflammatory agent/
45. nsaid$.tw.
46. nonsteroidal anti-inflammator$.tw.
47. non-steroidal anti-inflammator$.tw.
48. exp diclofenac/
49. diclofenac$.tw.
50. fenoprofen$.tw.
51. flurbiprofen$.tw.
52. exp indometacin/
53. indometacin$.tw.
54. exp ketoprofen/
55. ketoprofen$.tw.
56. ketorolac$.tw.
57. exp piroxicam/
58. piroxicam$.tw.
59. bromfenac$.tw.
60. nepafenac$.tw.
61. oxyphenbutazone$.tw.
62. suprofen$.tw.
63. or/44-62
64. exp analgesia/
65. analgesi$.tw.
66. eye pain/
67. pain$.tw.
68. or/64-67
69. 43 and 63 and 68
70. 32 and 69
Appendix 4. LILACS search strategy
injur$ or abrasion or erosion or trauma or foreign bod$ and eye$ or cornea$ and nonsteroidal antiinflammator$ or nonsteroidal anti
inflammator$ or non steroidal anti inflammator$ or NSAID$ or diclofenac or fenoprofen or flurbiprofen or indometacin or ketoprofen
or ketorolac or piroxicam or bromfenac or nepafenac or oxyphenbutazone or suprofen and analgesi$ or pain$
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Appendix 5. OpenGrey search strategy
corneal abrasion and pain
Appendix 6. Zetoc search strategy
corneal abrasion and pain
Appendix 7. ISRCTN search strategy
corneal abrasion and pain
Appendix 8. ClinicalTrials.gov search strategy
Corneal Abrasion AND Pain
Appendix 9. WHO ICTRP search strategy
Corneal Abrasion AND Pain
Appendix 10. Risk of bias assessment
Risk of bias assessment (RoB assessment) Risk of bias assessment
Entry Judgement Support for judgement
1. Random sequence generation (selection
bias)
Low risk/High risk/Unclear risk Quote:
2. Allocation concealment (selection bias) Low risk/High risk/Unclear risk Quote:
3. Masking of participants and personnel
(performance bias)
Low risk/High risk/Unclear risk Quote:
4. Masking of outcome assessment (detec-
tion bias)
Low risk/High risk/Unclear risk Quote:
5. Incomplete outcome data Low risk/High risk/Unclear risk Quote:
Date: / / Reviewer’s signature:
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the protocol we stated that we would make additional efforts to identify potential RCTs relevant to the topic from the following
data sources: references (and references of references) cited in primary sources; other unpublished sources known to experts in the
specialty, raw data from published trials; contacting pharmaceutical companies. In this review, due to the comprehensive nature of our
electronic searches, we did not seek information regarding potential RCTs relevant to the topic from known experts in the specialty or
from pharmaceutical companies, and we did not seek raw data from the published trials.
We stated in the protocol that dichotomous outcomes would be described using relative (risk ratio) and absolute (risk difference)
measures. In this review we only calculated risk ratios. Measures of absolute risk are included in the summary of findings table.
42Topical non-steroidal anti-inflammatory drugs for analgesia in traumatic corneal abrasions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
